ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Reply to V. Fallet et al.
Abstract readLetterComment
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging cancer risks in BRCA2 pathogenic germline variant carriers.European journal of human genetics : EJHG · 2023Article
Corrections and comments
- Comment onDo Female2022
Authors and funding
8 authors.
Shuai LiShuai Li, MD, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia; Valentina Silvestri, PhD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; Timothy R. Rebbeck, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, Dana-Farber Cancer Institute, Boston, MA; Susan L. Neuhausen, PhD, Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA; John L. Hopper, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia; Henriette Roed Nielsen, PhD, Department of Clinical Genetics, Odense University Hospital, Odence, Denmark; Laura Ottini, MD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; and Antonis C. Antoniou, PhD, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-8696-8594
Valentina SilvestriShuai Li, MD, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia; Valentina Silvestri, PhD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; Timothy R. Rebbeck, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, Dana-Farber Cancer Institute, Boston, MA; Susan L. Neuhausen, PhD, Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA; John L. Hopper, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia; Henriette Roed Nielsen, PhD, Department of Clinical Genetics, Odense University Hospital, Odence, Denmark; Laura Ottini, MD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; and Antonis C. Antoniou, PhD, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-0712-9379
Timothy R RebbeckShuai Li, MD, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia; Valentina Silvestri, PhD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; Timothy R. Rebbeck, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, Dana-Farber Cancer Institute, Boston, MA; Susan L. Neuhausen, PhD, Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA; John L. Hopper, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia; Henriette Roed Nielsen, PhD, Department of Clinical Genetics, Odense University Hospital, Odence, Denmark; Laura Ottini, MD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; and Antonis C. Antoniou, PhD, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-4799-1900
Susan L NeuhausenShuai Li, MD, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia; Valentina Silvestri, PhD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; Timothy R. Rebbeck, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, Dana-Farber Cancer Institute, Boston, MA; Susan L. Neuhausen, PhD, Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA; John L. Hopper, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia; Henriette Roed Nielsen, PhD, Department of Clinical Genetics, Odense University Hospital, Odence, Denmark; Laura Ottini, MD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; and Antonis C. Antoniou, PhD, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-5053-0390
John L HopperShuai Li, MD, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia; Valentina Silvestri, PhD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; Timothy R. Rebbeck, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, Dana-Farber Cancer Institute, Boston, MA; Susan L. Neuhausen, PhD, Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA; John L. Hopper, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia; Henriette Roed Nielsen, PhD, Department of Clinical Genetics, Odense University Hospital, Odence, Denmark; Laura Ottini, MD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; and Antonis C. Antoniou, PhD, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-8567-173X
Henriette Roed NielsenShuai Li, MD, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia; Valentina Silvestri, PhD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; Timothy R. Rebbeck, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, Dana-Farber Cancer Institute, Boston, MA; Susan L. Neuhausen, PhD, Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA; John L. Hopper, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia; Henriette Roed Nielsen, PhD, Department of Clinical Genetics, Odense University Hospital, Odence, Denmark; Laura Ottini, MD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; and Antonis C. Antoniou, PhD, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Laura OttiniShuai Li, MD, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia; Valentina Silvestri, PhD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; Timothy R. Rebbeck, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, Dana-Farber Cancer Institute, Boston, MA; Susan L. Neuhausen, PhD, Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA; John L. Hopper, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia; Henriette Roed Nielsen, PhD, Department of Clinical Genetics, Odense University Hospital, Odence, Denmark; Laura Ottini, MD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; and Antonis C. Antoniou, PhD, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8030-0449
Antonis C AntoniouShuai Li, MD, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia; Valentina Silvestri, PhD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; Timothy R. Rebbeck, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, Dana-Farber Cancer Institute, Boston, MA; Susan L. Neuhausen, PhD, Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA; John L. Hopper, PhD, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia; Henriette Roed Nielsen, PhD, Department of Clinical Genetics, Odense University Hospital, Odence, Denmark; Laura Ottini, MD, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy; and Antonis C. Antoniou, PhD, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-9223-3116
Funding
Precision Assessment and Delivery of Cancer Risks in BRCA 1/2 Mutation CancersR01CA207365 · NCI · DANA-FARBER CANCER INST · PI CHEN, JINBO, REBBECK, TIMOTHY R · 2017 to 2021
$3.6MCancer Research UK 20861NCI NIH HHS R01 CA207365
Abstract
PubMed holds no abstract for this paper.
Identifiers
PMID
35549306What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.